Home > Back to Publisher > Report Information

Expanding a Brand: Statins and PPAR-Gamma Agonists to Treat Neurological Disease

Decision Resources
December 18, 2006
17 Pages - SKU: DECR1399792

Abstract Table of Contents Related Reports

Introduction:

The repositioning of agents to treat neurodegenerative disorders represents a signifi cant opportunity for companies that have products in highly competitive markets. Although the value of neurodegenerative markets is small by comparison, the signifi cant unmet need and the severity of these diseases mean that an emerging agent that can offer even a modest improvement over available therapies is likely to establish a share in the market.

Get the Answers You Need to Shape Your Strategy:

Both Alzheimer's disease (AD) and multiple sclerosis (MS) have relatively small patient populations. Nevertheless, what factors make these two markets especially appealing to drug developers interested in repositioning their drugs?

Similarities between the pathogenesis of AD and the pathogenesis of cardiovascular disease suggest that statins may have some effect on AD. What are the similarities, and what have been the results of clinical trials thus far?

Likewise, there are a number of connections between insulin metabolism and AD. Diabetes is, in fact, a risk factor for AD. What are the connections, and what have been the results of clinical trials investigating the effect of PPAR-gamma agonists on AD?

Pfizer and GlaxoSmithKline are two major drug developers actively seeking to reposition their products into the neurological markets (Pfi zer with its statin Lipitor [atorvastatin] and GlaxoSmithKline with its PPAR-gamma agonist Avandia [rosiglitazone]). What are the factors behind these companies' decisions to investigate new markets?

Scope:

The AD therapy market: key statistics.
The MS therapy market: key statistics.
Use of statins in treating AD: similarities in disease pathophysiology and clinical support for statin use.
Use of statins in treating MS: similarities in disease pathophysiology and clinical support for statin use.
Use of PPAR-gamma agonists in treating AD: similarities in disease pathophysiology and clinical support for statin use.

Please note, the PDF e-mail from publisher version of this report is for a global site license.

Additional Information

Mentioned in This Spectrum Report:

Companies/Institutes

Bayhill Therapeutics
Biogen Idec
Eisai
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Merck
National Institute on Aging
Pfi zer
Serono
Sun Research Institute
Takeda
Teva Pharmaceuticals

Drugs

Actos (pioglitazone)
Aricept (donepezil)
Avandia (rosiglitazone)
Avonex (interferon beta-1a)
BHT-3009
Copaxone (glatiramer acetate)
Lipitor (atorvastatin)
Rebif (interferon beta-1a)
Topamax (topiramate)
Zocor (simvastatin)

Expanding a Brand: Statins and PPAR-Gamma Agonists to Treat Neurological Disease

Share this report

Other tasks

Research Assistance

Related Markets

CNS/Neurology Reports

Free Alert Me service